Analyzers
These analyzers are used for disease testing for heart disease, cancer, diabetes, infectious diseases and hormonal disorders related to lifestyle.
Analyzers
These analyzers are used for disease testing for heart disease, cancer, diabetes, infectious diseases and hormonal disorders related to lifestyle.

Next Generation Automated
Immunoassay System
ALFIS-3 is an ELISA based POC immunoassay analyzer. ALFIS-3 has a built-in automated fluorescence scanning system using magnetic beads and alkaline phosphatase enzyme system for the quantitative immunoassay. ALFIS-3 tests are used for measuring the concentration of various analytes in human blood, plasma, and serum. ALFIS-3 tests are in vitro diagnostic tests intended for screening, monitoring and/or routine physical examination in centralized laboratories of hospitals and physician clinics.
For information to enhance your ALFIS-3 experience or if you'd like more information on our all in one cartridge release schedule contact us here.
The ALFIS-3 is currently Export Only.

Compact Fast Reliable
The ALFIS-3 features
Fully Automatic
LIS Connectivity
3 Simultaneous Testing Channels
Capillary Blood, Serum or Plasma
7" LCD Touch Screen
Broad test portfolio
Fertility
-
Total Beta hCG
-
Progesterone
-
17 Beta Estadiol
-
Testosterone
-
Procalactin
-
AMH
-
FSH
-
LH
Cardiac
-
Myoglobulin
-
Troponin-1
-
NTproBNP
-
D-Dimer
-
CK-MB
-
ST2
Thyroid
-
Free T4
-
Free T3
-
TSH
Tumor
-
Free PSA
-
AFP
Other
-
25OH Vitamin D Total
-
Vitamin B12


ALFIS-3
Technical Specifications
Throughput
Number of channels
Sample
Cartridge
Measuring principle
Monitor/Keyboard
Calibration
Connectivity
Power Input
Dimension / Weight
Instrument type
Temp. Control
22min per test / Up to 6 tests per hour
Simultaneous triple testing*
Serum/Plasma (20~100 ul), W/B (10-30 ul)
Ready to use “all in one cartridge”
Enzyme linked fluorescence immunoassay
7” LCD touch screen, built-in thermal printer Bluetooth Keyboard (optional)
Factory calibration, 2-point calibration / ID Chip (Master Calibration Curve)
LIS/HIS compatible, RS 232, USB port, Ethernet, SD card slot
100 ~ 240 V AC (50/60 Hz) / 360VA
422 (D) x 270 (W) x 292 mm (H) / 10.0 Kg
Compact Automatic Immunoassay Analyzer
Internal temperature control
* Simultaneous testing available within certain parameters

ALFIS-3 Resources

Sample type | Anterior nares swab |
Time to results | 15 minutes |
Kit storage conditions | Room temperature (2°C to 30°C/36°F to 86°F) |
Internal controls | Included |
PPA (Reference Extracted SARS-CoV-2 RT-PCR Assay) | 87.3% |
NPA (Reference Extracted SARS-CoV-2 RT-PCR Assay) | 100% |
In the USA, this product has not been FDA cleared or approved; but has been authorized by FDA under an EUA;
·This product has been authorized only for the detection of proteins from SARS- CoV-2, not for any other viruses or pathogens; and,
·The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
·For more information on EUAs please visit:
https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergencyuse-authorization
·For the most up to date information on COVID-19, please visit: www.cdc.gov/COVID19
Swab-N-Go Home test COVID-19 Ag 2T (Cat. #: CFPT-17)
Kit Includes:
Swabs: | 2 ea |
Test cartridge: | 2 ea |
Extraction tubes: | 2 ea |
Nozzles: | 2 ea |
Quick Reference Instruction: | 1 ea |
Have a watch or timer ready (nor included in the kit)
Avaliable for bulk purchase. For further details, please contact us using the information provided below
Having symptoms of weakness, dizziness, pale skin and cold hands and feet, Parents or other immediate family members have had a history of any blood disorder, If current diet is very low in iron and mineral content, Suffering from a long-term infection, They have suffered an excessive blood loss due to injury or surgical procedure, They are pregnant.
Having symptoms of weakness, dizziness, pale skin and cold hands and feet, Parents or other immediate family members have had a history of any blood disorder, If current diet is very low in iron and mineral content, Suffering from a long-term infection, They have suffered an excessive blood loss due to injury or surgical procedure, They are pregnant.
hema-screen SPECIFIC, a Fecal Immunochemical Test (FIT), is a rapid, convenient qualitative immunoassay for the determination of human hemoglobin in feces, a vital tool in the diagnosis and therapy of gastrointestinal disorders. Studies show that the following risk factors increase a person's chances of developing colorectal cancer:
• Age: colorectal cancer can occur at younger ages
• Diet (high in fat and calories and low in fiber or high in red or processed meat)
• Obesity; Physical inactivity; Cigarette smoking; Heavy alcohol consumption
• History or familial polyposis (parents, siblings, children
• Persons having ulcerative colitis or crohn’s disease
In comparison with guaiac-based testing the hema-screen SPECIFIC test has a higher specificity due to its unique combination of monoclonal and polyclonal antibodies that are specific to human-globin. A traditional guaiac test reacts with the peroxidase activity of heme protein in blood and is non-specific for human hemoglobin.
hema-screen™ SPECIFIC features an innovative sampling method that utilizes one card for collection of two (2) specimens of feces and ONLY one immunochemical specimen preparation tube/test cassette system for analysis. Advantages of utilizing the DEVEL-A-TAB sampler are as follows: thirty (30) days stability; and if the card is not returned the buffer tube and cassette are still useable. In addition, the replacement of the DEVEL-A-TAB sampler and mailing costs are reduced in comparison to the replacement of the buffer tube.
Since hema-screen™ SPECIFIC detects only blood from the lower GI tract where polyps and colorectal cancer develop, the test was found to be more accurate than a leading guaiac-based FOBT. In clinical studies, hema-screen™ SPECIFIC demonstrated a sensitivity of 98% and a specificity of 99%. When compared with a guaiac-based FOBT, hema-screen™ SPECIFIC demonstrated 33% greater sensitivity for occult blood.
There is no fecal handling involved when performing sample collections. Rather, samples are taken by defecating onto a tissue and using an applicator stick to stab the stool in 4-6 different sites. Once the sample is collected on the applicator lay the DEVEL-A-TAB sampler on a flat surface and apply the sample to window #1 by pulling the applicator stick across the entire window, making sure that the cavity is evenly filled and leveled. Close flap. Release tissue and FLUSH tissue and discard applicator stick.
Check that there is not excess specimen in the tube. Use stick attached to tube cap to loosen feces from sample strip if dispersion of specimen seems inadequate. Shake the tube vigorously (or vortex or rotator mix) to ensure the feces is well mixed with the buffer. Some small amount of fecal matter may not go into solution. There should not be any significant amount of undissolved fecal matter in the preparation tube. If the buffer flow along the test cassette appears to have stopped. First, tap cassette lightly on a hard surface, if flow does not continue, dispense one or more further drops into the test cassette well. If the test continues to not develop the patient should be supplied another collection kit and instructed to perform sample collection in accordance with the instructions for use. If there is no excess specimen and the test still does not develop within 5 minutes after the application of 2 additional drops of buffer, please contact Technical Services, Immunostics, Inc. in the US: 1-800-722-7505.
hema-screen SPECIFIC detects human blood in stool. There are many gastrointestinal conditions that may cause blood in stool, aside from colorectal cancer. If a patient receives a positive test result, more testing and evaluation is necessary and the American Cancer Society recommends follow-up with a colonoscopy.
Higher accuracy is achieved when testing is performed on two (2) consecutive fecal samples due to intermittent bleeding. The hema-screen SPECIFIC kit (Cat. №: HSSP-25) meets the American Cancer Society and the U.S. Task Force for Colorectal Cancer (CRC) Foundation recommendation of multiple-day testing.





